(Q33390876)

PubMed publication ID

26 July 2017

1 reference

title

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

1 reference

ChEBI release 2020-05-28

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

9

Susan E Bates

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

William Douglas Figg, Sr.

13 May 2020

8

object named as

William D Figg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

3

Richard Piekarz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

author name string

Cliona Grant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

Fahd Rahman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

Cody Peer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

Robin Frye

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

Erin R Gardner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

language of work or name

1 reference

1 July 2010

1 reference

PubMed publication ID

20645688

Expert Review of Anticancer Therapy

26 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

page(s)

997-1008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

Histone deacetylase inhibitors: overview and perspectives

13 May 2020

cites work

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

21 January 2018

1 reference

Histone deacetylases and cancer

21 January 2018

1 reference

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells

21 January 2018

1 reference

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

21 January 2018

1 reference

Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes

21 January 2018

1 reference

Medicinal importance of grapefruit juice and its interaction with various drugs

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors

21 January 2018

1 reference

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

Epigenetic modifiers: basic understanding and clinical development.

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

21 January 2018

1 reference

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

21 January 2018

1 reference

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

21 January 2018

1 reference

Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.

21 January 2018

1 reference

Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines.

21 January 2018

1 reference

Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents

21 January 2018

1 reference

Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells

21 January 2018

1 reference

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

Induction of MAGE-3 expression in lung and esophageal cancer cells

21 January 2018

1 reference

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

21 January 2018

1 reference

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

Glucose metabolism as a target of histone deacetylase inhibitors.

21 January 2018

1 reference

Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.

21 January 2018

1 reference

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

21 January 2018

1 reference

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

Cardiac involvement with lymphoma: a review of the literature

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Cardiovascular toxicity of molecularly targeted agents.

21 January 2018

1 reference

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

21 January 2018

1 reference

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

Introducing a new entity: chemotherapy-induced arrhythmia.

21 January 2018

1 reference

Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

21 January 2018

1 reference

Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma

21 January 2018

1 reference

Rational combinations using HDAC inhibitors

21 January 2018

1 reference

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias

21 January 2018

1 reference

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

21 January 2018

1 reference

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

21 January 2018

1 reference

Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors

21 January 2018

1 reference

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

Inhibition of histone deacetylation: a strategy for tumor radiosensitization

21 January 2018

1 reference

Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.

21 January 2018

1 reference

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

21 January 2018

1 reference

Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.

21 January 2018

1 reference

5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer).

21 January 2018

1 reference

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells

21 January 2018

1 reference

12 December 2020

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

12 December 2020

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

1 reference

12 December 2020

Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.

1 reference

12 December 2020

Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series

1 reference

12 December 2020

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

1 reference

12 December 2020

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

1 reference

12 December 2020

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

1 reference

12 December 2020

Histone deacetylase inhibitors: emerging anticancer therapeutic agents?

1 reference

12 December 2020

Cardiac safety, risk management, and oncology drug development

1 reference

12 December 2020

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

12 December 2020

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

12 December 2020

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

12 December 2020

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report

1 reference

12 December 2020

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

1 reference

12 December 2020

Regulation of the HIF-1alpha stability by histone deacetylases

1 reference

12 December 2020

HDAC inhibitors and cardiac safety

1 reference

12 December 2020

FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70

1 reference

12 December 2020

Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies

1 reference

12 December 2020

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells

1 reference

12 December 2020

Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)

1 reference

12 December 2020

Evaluation of an electrolyte replacement protocol in an adult intensive care unit: a retrospective before and after analysis

1 reference

12 December 2020

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

1 reference

12 December 2020

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1 reference

12 December 2020

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice

1 reference

12 December 2020

Identifiers

DOI

10.1586/ERA.10.88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6361116&resulttype=core&format=json

13 May 2020

PubMed publication ID

20645688

1 reference